Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Paclitaxel + PHST001 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PHST001 | PHST 001|PHST-001 | CD24 Antibody 3 | PHST001 is a monoclonal antibody targeting CD24, which potentially induces macrophage-dependent tumor cell phagocytosis and inhibits tumor growth (Journal for ImmunoTherapy of Cancer 2024;12). | |
| Paclitaxel | Taxol | 7-Epipaclitaxel | Antimicrotubule Agent 14 BCL2 Family Inhibitor 6 | Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06840886 | Phase I | PHST001 Doxorubicin + PHST001 Fluorouracil + Irinotecan + Leucovorin + PHST001 Fluorouracil + Leucovorin + Oxaliplatin + PHST001 Gemcitabine + PHST001 Paclitaxel + PHST001 PHST001 + Topotecan | A Study of PHST001 in Advanced Solid Tumors | Recruiting | USA | 0 |